ROIV vs. ZTS: Roivant Sciences vs. Zoetis Stock Comparison

November 11, 2026

How do Roivant Sciences (ROIV) and Zoetis (ZTS) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Roivant Sciences (ROIV) and Zoetis (ZTS) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ROIV is classified in Biotechnology while ZTS is classified in Pharmaceuticals.

Company profile comparison for Roivant Sciences (ROIV) and Zoetis (ZTS)
Profile Item	ROIV	ZTS
Name	Roivant Sciences Ltd.	Zoetis Inc. Class A Common Stock
Country/Region	United Kingdom	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology	Pharmaceuticals
GICS Sub-Industry	Biotechnology	Pharmaceuticals
Market Capitalization	28.08 billion USD	32.26 billion USD
Currency	USD	USD
Exchange	Nasdaq	NYSE
Listing Date	December 8, 2020	February 1, 2013
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

ROIV

ZTS

GSPC

Roivant Sciences (ROIV) vs. Zoetis (ZTS), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Roivant Sciences (ROIV) and Zoetis (ZTS). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Roivant Sciences (ROIV) and Zoetis (ZTS). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Roivant Sciences (ROIV) and Zoetis (ZTS)
Metric	ROIV	ZTS
Total Return (1Y)	96.75%	-30.10%
Total Return (3Y, Annualized)	68.04%	-20.42%
Total Return (5Y, Annualized)	36.73%	-16.87%

Risk Profile

Drawdown History

ROIV

ZTS

GSPC

Roivant Sciences (ROIV) vs. Zoetis (ZTS), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Roivant Sciences (ROIV) and Zoetis (ZTS). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Roivant Sciences (ROIV) and Zoetis (ZTS)
Metric	ROIV	ZTS
Volatility (1Y, Annualized)	47.99%	38.23%
Beta (5Y)	1.17	0.66
Max Drawdown (5Y)	-79.22%	-70.45%
Avg. Volume (3M)	7.82M	4.65M

Risk-Adjusted Performance

Risk-Return Positioning

ROIV and ZTS are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Roivant Sciences (ROIV) and Zoetis (ZTS)
Metric	ROIV	ZTS
Sharpe Ratio (1Y)	1.93	-0.90
Sortino Ratio (1Y)	4.03	-1.10

Profitability

ROE (TTM)

Roivant Sciences (ROIV) reports a negative ROE of -8.52%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Zoetis (ZTS) reports 57.63%, ranking against industry peers normally.

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

-8.52%

Max: 109.18%
Q3: 6.23%
ROIV: -8.52%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

57.63%

Max: 109.18%
ZTS: 57.63%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Roivant Sciences (ROIV) vs. Zoetis (ZTS): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Zoetis (ZTS) at 26.41% converts revenue to bottom-line profit above its industry’s benchmark range, while Roivant Sciences (ROIV) at 0.00% keeps roughly the typical share for its industry.

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max: 18.05%
Q3: 4.78%
ROIV: 0.00%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

26.41%

ZTS: 26.41%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Roivant Sciences (ROIV) vs. Zoetis (ZTS): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Roivant Sciences (ROIV) reports a negative operating margin of -25,408.11%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Zoetis (ZTS) reports 38.19%, ranking against industry peers normally.

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

-25,408.11%

Max: 83.12%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%
ROIV: -25,408.11%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

38.19%

Max: 83.12%
ZTS: 38.19%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Roivant Sciences (ROIV) vs. Zoetis (ZTS): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Roivant Sciences (ROIV) and Zoetis (ZTS)
Metric	ROIV	ZTS
ROE (TTM)	-8.52%	57.63%
ROA (TTM)	-16.28%	14.87%
Net Margin (TTM)	0.00%	26.41%
Operating Margin (TTM)	-25,408.11%	38.19%
Gross Margin (TTM)	0.00%	71.65%

Growth

Revenue Growth

Zoetis (ZTS) at 2.28% is around its peer norm for revenue growth, while Roivant Sciences (ROIV) at -71.57% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Roivant Sciences (ROIV) vs. Zoetis (ZTS): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: Zoetis (ZTS) reports EPS growth of 10.05%, ranked against its industry; Roivant Sciences (ROIV) has no EPS growth figure this period.

Roivant Sciences (ROIV) vs. Zoetis (ZTS): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Roivant Sciences (ROIV) and Zoetis (ZTS)
Metric	ROIV	ZTS
Revenue Growth (YoY)	-71.57%	2.28%
Revenue Growth (3Y CAGR)	-36.01%	5.42%
EPS Growth (YoY)	--	10.05%
EPS Growth (3Y CAGR)	--	10.27%

Financial Strength

Current Ratio (MRQ)

Roivant Sciences (ROIV) at 16.72 carries current ratio above its industry’s typical mid-range, while Zoetis (ZTS) at 2.35 runs in the tighter-liquidity quartile — different working-capital profiles, both worth examining.

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

16.72

Max: 25.13
ROIV: 16.72
Q3: 12.13
Median: 5.52
Q1: 2.47
Min: 0.10

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.35

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
ZTS: 2.35
Min: 0.10

Roivant Sciences (ROIV) vs. Zoetis (ZTS): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Roivant Sciences (ROIV) at 0.02 is near its industry mid-range for debt-to-equity ratio, while Zoetis (ZTS) at 2.80 sits above its benchmark range, pointing to a heavier debt load relative to equity.

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.02

Max: 1.42
Q3: 0.65
Median: 0.15
ROIV: 0.02
Q1: 0.02
Min: 0.00

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.80

ZTS: 2.80
Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

Roivant Sciences (ROIV) vs. Zoetis (ZTS): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Roivant Sciences (ROIV) and Zoetis (ZTS)
Metric	ROIV	ZTS
Current Ratio (MRQ)	16.72	2.35
Debt / Equity (MRQ)	0.02	2.80
Net Debt / EBITDA	--	1.92

Dividends

Dividend Yield (TTM)

Roivant Sciences (ROIV) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Zoetis (ZTS) reports a yield of 2.55%, ranking against industry peers normally.

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ROIV: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.55%

ZTS: 2.55%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Roivant Sciences (ROIV) vs. Zoetis (ZTS): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Roivant Sciences (ROIV) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Zoetis (ZTS) reports a payout of 35.24%, ranking against industry peers normally.

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ROIV: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

35.24%

ZTS: 35.24%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Roivant Sciences (ROIV) vs. Zoetis (ZTS): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Roivant Sciences (ROIV) and Zoetis (ZTS)
Metric	ROIV	ZTS
Dividend Yield (TTM)	0.00%	2.55%
Dividend Payout Ratio (TTM)	0.00%	35.24%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: Zoetis (ZTS) trades at 13.50 times trailing earnings, ranked against its peers, while Roivant Sciences (ROIV) has no P/E ratio this period.

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07
ROIV: --

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.50

Max: 85.34
Q3: 43.46
Median: 26.69
ZTS: 13.50
Q1: 13.30
Min: 0.07

Roivant Sciences (ROIV) vs. Zoetis (ZTS): ROIV does not report P/E ratio, so it has no value marker; ZTS is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

Zoetis (ZTS) at 3.40 prices around its industry’s typical P/S ratio, while Roivant Sciences (ROIV) at 3,728.61 clears its benchmark range — ROIV looks notably rich on sales.

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

3,728.61

ROIV: 3,728.61
Max: 58.18
Q3: 25.77
Median: 7.30
Q1: 3.01
Min: 0.01

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.40

Max: 58.18
Q3: 25.77
Median: 7.30
ZTS: 3.40
Q1: 3.01
Min: 0.01

Roivant Sciences (ROIV) vs. Zoetis (ZTS): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Both Roivant Sciences (ROIV) at 6.64 and Zoetis (ZTS) at 9.80 carry a premium to book value versus peers, sitting in the upper P/B ratio quartile of their industries.

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.64

Max: 13.53
ROIV: 6.64
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.80

Max: 13.53
ZTS: 9.80
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

Roivant Sciences (ROIV) vs. Zoetis (ZTS): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Roivant Sciences (ROIV) and Zoetis (ZTS)
Metric	ROIV	ZTS
P/E Ratio (TTM)	--	13.50
P/S Ratio (TTM)	3,728.61	3.40
P/B Ratio (MRQ)	6.64	9.80
Free Cash Flow Yield (TTM)	-3.98%	6.36%